BioCatalystWatch
SLSWorkspace / SLS / OverviewCompany library
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. (SLS)

Website

Price
Market cap
Next catalystDec 14, 2026SLS009 (tambiciclib) + azacitidine/venetoclax — completed r/r AML study · Phase 2 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

SLS009 (tambiciclib)SLS009 (tambiciclib) + azacitidine/venetoclax — completed r/r AML study

CDK9

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

SLS009 (tambiciclib)SLS009 (tambiciclib) + azacitidine/venetoclax — completed r/r AML study

CDK9

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

NPS

HER2

PreINDP1P2P3FilingApproved

History / paused

WT1

PreINDP1P2P3FilingApproved

WT1

PreINDP1P2P3FilingApproved

WT1

PreINDP1P2P3FilingApproved

WT1

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

SLS PR & News

PR & News

SLS SEC archive